Home › Funds › Sanofi › INBX

Sanofi position in INBX

INHIBRX BIOSCIENCES INC · Health Care

Sanofi reported holding 1,157,926 shares of INBX (INHIBRX BIOSCIENCES INC) in its Q3 2026 13F filing — a position valued at US$115.9M, representing 18.40% of its reported portfolio and ranking #2 among its reported holdings. Sanofi has disclosed INBX holdings in 8 of the last 8 reported quarters, going back to Q4 2024.

Latest position (Q3 2026)1.16M sh
Reported value held$115.89M
Portfolio Weight18.40%
First reportedQ4 2024
Last changeHold
Updated2026-11-05

Last updated: 2026-11-05 · Source: SEC EDGAR Form 13F-HR

How Sanofi's INBX position evolved

Sanofi first disclosed a stake in INBX in Q4 2024 at 1,157,926 shares (US$17.8M). The position peaked in Q3 2026 at 1,157,926 shares, worth US$115.9M. Across 8 filings, Sanofi held the position steady without any share-count change. The most recent filing (Q3 2026) shows 1,157,926 shares valued at US$115.9M.

Quarter by quarter

QuarterSharesValueChange
Q4 2024 1.16M $17.83M New
Q1 2025 1.16M $16.20M Hold
Q2 2025 1.16M $16.52M Hold
Q3 2025 1.16M $39.00M Hold
Q4 2025 1.16M $91.48M Hold
Q1 2026 1.16M $77.85M Hold
Q2 2026 1.16M $109.71M Hold
Q3 2026 1.16M $115.89M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About INBX and 13F data

INBX (INHIBRX BIOSCIENCES INC) is a Health Care company. 43 other funds we track also report a position in INBX — the largest reported positions include PERCEPTIVE ADVISORS LLC (US$123.0M), Schonfeld Strategic Advisors LLC (US$66.1M), PFM Health Sciences, LP (US$29.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding INBX

All INBX fund holders →

FAQ

How long has Sanofi held INBX?

Sanofi has disclosed INBX holdings in 8 of the last 8 reported quarters, going back to Q4 2024.

What is Sanofi's current position in INBX?

As of Q3 2026, Sanofi holds 1.16M shares of INBX (INHIBRX BIOSCIENCES INC), valued at $115.89M, representing 18.40% of its reported portfolio and ranking #2.

Has Sanofi been buying or selling INBX?

In the latest 13F filing (Q3 2026), Sanofi held unchanged its position in INBX. The position peaked in Q3 2026 at 1.16M shares.

Which other funds hold INBX?

Other major institutional holders of INBX include PERCEPTIVE ADVISORS LLC, Schonfeld Strategic Advisors LLC, PFM Health Sciences, LP, among 43 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.